EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 110.28

Change

+1.66 (+1.53)%

Market Cap

USD 0.70B

Volume

5.54K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.20 (+0.39%)

USD 445.28B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.06 (+0.35%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.07 (+0.26%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.06 (+0.21%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.10 (+0.38%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.26 (+0.56%)

USD 104.21B
8R80:XETRA Amundi Index Solutions - Amund..

+0.56 (+0.39%)

USD 98.84B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.20 (+0.38%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.07 (+0.06%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-0.18 (-0.03%)

USD 80.38B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.92% 51% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.92% 51% F 49% F
Trailing 12 Months  
Capital Gain 2.82% 21% F 28% F
Dividend Return 1.40% 25% F 21% F
Total Return 4.21% 25% F 31% F
Trailing 5 Years  
Capital Gain 17.90% 45% F 50% F
Dividend Return 7.95% 50% F 38% F
Total Return 25.85% 48% F 51% F
Average Annual (5 Year Horizon)  
Capital Gain 7.09% 53% F 53% F
Dividend Return 8.11% 55% F 55% F
Total Return 1.01% 70% C- 50% F
Risk Return Profile  
Volatility (Standard Deviation) 8.22% 69% C- 76% C+
Risk Adjusted Return 98.57% 87% B+ 88% B+
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike